Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

This publication has 13 references indexed in Scilit:

• Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
  Journal of Clinical Oncology, 1999
• High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
  British Journal of Cancer, 1998
• Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
  Journal of Clinical Oncology, 1997
• Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
  Journal of Clinical Oncology, 1997
• Doxorubicin in sterically stabilized liposomes
  Nature, 1996
• A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
  New England Journal of Medicine, 1993
• Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
  Journal of Clinical Oncology, 1993
• Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
  Journal of Clinical Oncology, 1993
• Chemotherapy in the multidisciplinary approach to soft tissue sarcomas
  Annals of Oncology, 1992
• Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group
  European Journal of Cancer and Clinical Oncology, 1987